About this trial
Patients with combat-related amputations frequently experience persistent neuroma pain that may interfere with rehabilitation, prosthesis use, sleep, mobility, and quality of life. Current treatment options often provide only temporary relief. This study aims to compare two ultrasound-guided injection approaches for chronic neuroma pain after combat-related amputation: botulinum toxin type A and local anesthetic injection.
Participants will be randomly assigned to receive one of the two treatments. Pain intensity, neuropathic pain symptoms, phantom limb pain, prosthesis tolerance, and functional outcomes will be evaluated during follow-up visits over a 24-week period.
The goal of the study is to determine whether botulinum toxin type A provides longer-lasting pain reduction and improved functional recovery compared with local anesthetic injection in patients with chronic neuroma pain after combat-related amputation.
Eligibility criteria
Qualifiers
Age ≥18 years
Combat-related limb amputation
Persistent neuroma pain lasting ≥3 months
Ultrasound-confirmed neuroma
Disqualifiers
Active infection at the injection site
Previous botulinum toxin injection within 6 months
Previous neuroma surgery within 3 months
Severe uncontrolled psychiatric disorder
Trial design
Treatments tested in this trial
- Botulinum Toxin Type A (BoNT-A)
- Local Anesthetic Solution